Clearside Biomedical (CLSD) Stock Statistics & Valuation Metrics

Clearside Biomedical has a market cap or net worth of $60.22M. The enterprise value is $48.11M.

Clearside Biomedical has 77,708,534 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clearside Biomedical’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -137.00%.

The current PE Ratio of Clearside Biomedical is -2.04. Clearside Biomedical’s PEG ratio is -0.15.

In the last 12 months, Clearside Biomedical had revenue of 1.66M and earned -34.35M in profits. Earnings per share was -0.47.

In the last 12 months, operating cash flow was -22.68M and capital expenditures -920.00K, giving a free cash flow of -23.60M billion.

Clearside Biomedical pays an annual dividend of ―, resulting in a dividend yield of ―

Clearside Biomedical upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.

Clearside Biomedical as a current ratio of 4.44, with Debt / Equity ratio of -1.35%

In the past 12 months, Clearside Biomedical has paid 0.00 in taxes.

Clearside Biomedical EV to EBITDA ratio is -2.09, with an EV/FCF ratio of -1.98.

Clearside Biomedical has $13.63M in cash and marketable securities with $619.00K in debt, giving a net cash position of -$13.01M billion.

Gross margin is 89.61%, with operating margin of -1735.70%, and net profit margin of -2064.42%.

The average price target for Clearside Biomedical is $5.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy